Authors: O Ilkgul* MD H Aydede* MD Y Erhan* MD S Surucuoglu* MD H GazI* MD ( S Vatansever* PhD F Taneli* MD C Ulman* MD C Kose* MD S Bengmark†, MD, PhD.
Published: British Journal of Intensive care. 2005.
The study was conducted in vivo, involving animals.
Design: Randomly selected and divided.
Treatment: The rats were divided into eight groups, all getting different timing, frequencies and compositions administered.
Where and when: Experimental Animal Research Laboratory, Faculty of Medicine, Ege University, Izmir, Turkey.
Sample size: 80 rats.
Sample criteria: Male adult Wistar albino rats weighing 250–300 g were randomly selected.
Analysed material:
Results
A lung injury was produced using a modification of the caecal ligation and puncture (CLP) technique (s. 53). – 24 hours after induction of CLP, an indicator of PMN infiltration (infiltration into tissues during inflammation – plays a central role in innate immunity) was significantly lower in the LAB-treated groups. (s. 54).
Changes consistent with intense lung injury in the control groups were significantly reduced in the LAB-treated group. (s. 54).
The study demonstrates that treatment with synbiotics administered subcutaneously had an impact on modulating immune responses. Synbiotic treatment resulted in a reduction in inflammatory markers,, and enhanced anti-inflammatory responses.
Indicative results
Synbiotics administered subcutaneously show promise in reducing inflammation and improving outcomes in critically ill patients, suggesting an innovative application of probiotics beyond oral administration.
The findings highlight the potential of targeting immune modulation through probiotic therapies in critical care settings.
Clinical trials with larger sample sizes and diverse patient populations to validate the efficacy and safety of subcutaneous synbiotic administration.
Investigations into the mechanisms behind the observed immunomodulatory effects to provide deeper insights into how probiotics influence systemic immune responses.
Comparative studies exploring different administration routes and their impacts on outcomes.
Det ser ut til at du er i Norge. Besøk vår norske nettside her www.supersynbiotics.no
